Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants
Epistemonikos ID: ad49ad625ad561053b6ae2011858c15854c0dab8
First added on: May 07, 2024